CIK 0000882796
- Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 621413174
- Phone
- +1 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- 4 Planned sale Chief Legal Officer sold 62,500 shares at $9.54 ($596,250)
- 4 Grant or award Chief R&D Officer acquired 205,150 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 49,933 shares at $10.11 ($504,823)
- 4 Planned sale Chief Legal Officer sold 150,000 shares at $9.15 ($1,372,500)
- 4 Grant or award Director acquired 528 shares (grant or award)
- 4 Returned to the company Director returned 305,995 shares (to the company)
- 4 Grant or award Director acquired 848 shares (grant or award)
- 4 Grant or award Director acquired 1,285 shares (grant or award)
- 4 Grant or award Director acquired 642 shares (grant or award)
- 4 Grant or award Director acquired 14,854 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Shares withheld for taxes Chief Executive Officer gave up 61,793 shares (to pay taxes)
- 4 Planned sale Chief Legal Officer sold 21,773 shares at $7.65 ($166,563)
- 4 Option exercise President and CCO acquired 74,233 shares (option exercise)
- 4 Gift Chief Executive Officer gave 20,000 shares (gift)
- 4 Grant or award President and CCO acquired 471,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 121,700 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 121,700 shares (grant or award)
Page 2 of 49 · 965 filings